Wolkenstein P., Latarjet J., Roujeau J.C., et al. (1998). Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.

Lancet Lond Engl, 352(9140), 1586 - 1589.

Schwartz R.A., McDonough P.H., and Lee B.W. (2013). Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol, 69(2), 173.e1 - 13; quiz 185 - 186.

Creamer D., Walsh S.A., Dziewulski P., et al. (2016). U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal

necrolysis in adults 2016. Br J Dermatol, 174(6), 1194 - 1227.

Chung W.H., Wang C.W., and Dao R.L. (2016). Severe cutaneous adverse drug reactions. J Dermatol, 43(7), 758 - 766.

Su S.C., Mockenhaupt M., Wolkenstein P., et al. (2017). Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson

Syndrome/Toxic Epidermal Necrolysis. J Invest Dermatol, 137(5), 1065 - 1073.

Lương Đức Dũng (2014). Nghiên cứu đặc điểm lâm sàng, cận lâm sàng, mô bệnh học và hoá mô miễn dịch ở bệnh nhân dị ứng thuốc có hội

chứng Stevens-Johnson và Lyell, Luận án Tiến sỹ Y học, Trường Đại học Y Hà Nội.

Su S.C. and Chung W.H. (2014). Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions. Toxins, 6(1), 194 - 210.

Nassif A., Bensussan A., Boumsell L., et al. (2004). Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol, 114(5), 1209 - 1215.

Fricke-Galindo I., LLerena A., and LópezLópez M. (2017). An update on HLA alleles associated with adverse drug reactions. Drug Metab Pers Ther, 32(2), 73 - 87.

Chung W.-H. and Hung S.-I. (2010). Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis. Allergol Int Off J Jpn Soc Allergol, 59(4), 325 - 332.

Nguyen D.V., Chu H.C., Nguyen D.V., et al. (2015). HLA-B*1502 and carbamazepineinduced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy, 5(2), 68 - 77.

Đỗ Thị Quỳnh Nga, Trần Thị Hải Âu, Vũ Thị Kim Liên và cộng sự (2015). Khảo sát liên quan giữa HLA-B*58:01 và nguy cơ mắc các phản

ứng dị ứng nặng do điều trị allopurinol tại Bệnh viện Bạch Mai, Hà Nội. 8(168), 396.

Bastuji-Garin S., Rzany B., Stern R.S., et al. (1993). Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol, 129(1), 92 - 96.

Sassolas B., Haddad C, and Mockenhaupt M. (2010). ALDEN, an algorthm for assessment of drug causality in Stevens-Johnson syndrome

and toxic epidermal necrolysis: compatison with case-control analysis. Clin Pharmacol Ther, 88(01), 60 - 68.

Man C.B.L., Kwan P., Baum L., et al. (2007). Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions

in Han Chinese. Epilepsia, 48(5), 1015 - 1018.

Hung S.I., Chung W.H., Liou L.B., et al. (2005). HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by

allopurinol. Proc Natl Acad Sci U S A, 102(11), 4134 - 4139.

Chung W.H., Chang W.C., Stocker S.L., et al. (2015). Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse

reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis, 74(12), 2157 - 2164.